dc.contributor.author | Catto, JWF | |
dc.contributor.author | North, B | |
dc.contributor.author | Goff, M | |
dc.contributor.author | Carter, A | |
dc.contributor.author | Sleeth, M | |
dc.contributor.author | Mandrik, O | |
dc.contributor.author | Chilcott, J | |
dc.contributor.author | Sasieni, P | |
dc.contributor.author | Cumberbatch, MGK | |
dc.date.accessioned | 2024-05-13T08:52:36Z | |
dc.date.available | 2024-05-13T08:52:36Z | |
dc.date.issued | 2024-03-26 | |
dc.identifier.citation | Catto JW, North B, Goff M, et alProtocol for the YORKSURe prospective multistage study testing the feasibility for early detection of bladder cancer in populations with high disease-specific mortality riskBMJ Open 2023;13:e076612. doi: 10.1136/bmjopen-2023-076612 | en_US |
dc.identifier.issn | 2044-6055 | |
dc.identifier.other | ARTN e076612 | |
dc.identifier.other | ARTN e076612 | |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/96801 | |
dc.description.abstract | Introduction Around 25% of patients with bladder cancer (BCa) present with invasive disease. Non-randomised studies of population-based screening have suggested reductions in BCa-specific mortality are possible through earlier detection. The low prevalence of lethal disease in the general population means screening is not cost-effective and there is no consensus on the best strategy. Yorkshire has some of the highest mortality rates from BCa in England. We aim to test whether population screening in a region of high mortality risk will lead to a downward stage-migration of aggressive BCa, improved survival and is cost-effective.
Methods and analysis YORKSURe is a tiered, randomised, multicohort study to test the feasibility of a large BCa screening randomised controlled trial. In three parallel cohorts, participants will self-test urine (at home) up to six times. Results are submitted via a mobile app or freephone. Those with a positive result will be invited for further investigation at community-based early detection clinics or within usual National Health Service (NHS) pathways. In Cohort 1, we will post self-testing kits to research engaged participants (n=2000) embedded within the Yorkshire Lung Screening Trial. In Cohort 2, we will post self-testing kits to 3000 invitees. Cohort 2 participants will be randomised between haematuria and glycosuria testing using a reveal/conceal design. In Cohort 3, we will post self-testing kits to 500 patients within the NHS pathway for investigation of haematuria. Our primary outcomes are rates of recruitment and randomisation, rates of positive test and acceptability of the design. The study is currently recruiting and scheduled to finish in June 2023. | en_US |
dc.publisher | BMJ Publishing Group | en_US |
dc.relation.ispartof | BMJ OPEN | |
dc.rights | This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. | |
dc.subject | bladder disorders | en_US |
dc.subject | mass screening | en_US |
dc.subject | urological tumours | en_US |
dc.title | Protocol for the YORKSURe prospective multistage study testing the feasibility for early detection of bladder cancer in populations with high disease-specific mortality risk | en_US |
dc.type | Article | en_US |
dc.rights.holder | © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ | |
dc.identifier.doi | 10.1136/bmjopen-2023-076612 | |
pubs.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:001068847000002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 9 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 13 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |